Sign in
Download Opera News App

DISEASE PREVENTION AND TREATMENT

GenSight Biologics Announces Positive Data Safety Monitoring Board Review of PIONEER Phase I/II Clinical Trial of GS030 as Optogenetic Treatment for Retinitis Pigmentosa

GenSight Biologics Announces Positive Data Safety Monitoring Board Review of PIONEER Phase I/II Clinical Trial of GS030 as Optogenetic Treatment for Retinitis Pigmentosa

DSMB finds no safety issue for highest dose of GS030 DSMB recommends selecting the highest dose (5e11 vg/eye) for extension cohort Recruitment of the extension cohort has been initiated Regulatory News: GenSight Biologics ((Euronext: SIGHT, OTC:GSGTF, PEA-PME eligible)), a biopharma company focused on developing and commercializing...

Read Full Story
DSMB Data Safety Monitoring Board Euronext GenSight Biologics OTC Regulatory News

Top News

US POLITICS

Newsom: Presidential bid has '100 percent never been on my radar'

thehill.com
Newsom: Presidential bid has '100 percent never been on my radar'

US POLITICS

Newsom: Presidential bid has '100 percent never been on my radar'

thehill.com

GOSSIP CELEBRITY

See singer and actor Nick Jonas through the years

usatoday.com
See singer and actor Nick Jonas through the years

GOSSIP CELEBRITY

See singer and actor Nick Jonas through the years

usatoday.com

comments

Load app to read more comments